ResearcherSichuan UniversityNo recent work listed
Lin Shui
Matched on ORCID iD 0000-0002-8666-0274; OpenAlex author ID A5011409222. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2020: 3 papers · 2021: 1 paper
Papers 4
- The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-021-02972-6↗
- Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for … Co-author DOI 10.1186/s12885-020-07126-3↗
- The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanced Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-60530/v1↗
- Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Ad… Co-author DOI 10.3389/fimmu.2020.01127↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yi Cheng · 3 shared papers, 2020–2021 · strength 0.34
- Paper Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemc… DOI 10.1186/s12885-020-07126-3↗
- Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
- Paper Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Pati… DOI 10.3389/fimmu.2020.01127↗
- Dan Cao · 3 shared papers, 2020–2021 · strength 0.34
- Paper Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemc… DOI 10.1186/s12885-020-07126-3↗
- Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
- Paper Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Pati… DOI 10.3389/fimmu.2020.01127↗
- Ke Cheng · 2 shared papers, 2020 · strength 0.23
- Paper Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemc… DOI 10.1186/s12885-020-07126-3↗
- Paper Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Pati… DOI 10.3389/fimmu.2020.01127↗
- Shuangshuang Li · 2 shared papers, 2020–2021 · strength 0.23
- Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
- Paper Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Pati… DOI 10.3389/fimmu.2020.01127↗
- Li Mao · 2 shared papers, 2020–2021 · strength 0.22
- Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
- Paper The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanc… DOI 10.21203/rs.3.rs-60530/v1↗
- Ang Li · 2 shared papers, 2020–2021 · strength 0.22
- Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
- Paper The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanc… DOI 10.21203/rs.3.rs-60530/v1↗
- Bole Tian · 2 shared papers, 2020–2021 · strength 0.22
- Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
- Paper The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanc… DOI 10.21203/rs.3.rs-60530/v1↗
- Heli Gao · 1 shared paper, 2021 · strength 0.12
- Ning An · 1 shared paper, 2021 · strength 0.12
- Dan Cao · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.